Drug
Everolimus
Data on this page refer exclusively to patients treated with
Everolimus combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
mTOR group page.
Drug Profile
| Therapeutic Class | Targeted Therapy |
| Drug Class | PI3K/AKT/mTOR Pathway Inhibitors |
| Group | mTOR |
| Mechanism of Action | mTOR inhibitor |
| Half-life | 30 h |
